Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report released on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a report on Thursday, November 14th.

Trevena Price Performance

Shares of NASDAQ:TRVN opened at $1.69 on Wednesday. Trevena has a 1 year low of $1.13 and a 1 year high of $19.23. The firm has a market capitalization of $1.45 million, a PE ratio of -0.04 and a beta of 1.08. The business’s 50 day moving average price is $2.27 and its 200-day moving average price is $5.03.

Trevena (NASDAQ:TRVN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The business had revenue of $0.28 million for the quarter. As a group, analysts expect that Trevena will post -23.04 earnings per share for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.